TP53 and B-cell chronic lymphocytic leukemia: Bomben et al. (2023) demonstrated that the simultaneous presence of TP53 deletions and mutations, irrespective of VAF, exerts a profound negative impact on the clinical outcomes of patients with CLL undergoing ibrutinib therapy [186].